[Systemic treatment of locally advanced or metastatic penile cancer].
Traitement systémique du cancer du pénis localement avancé ou métastatique.
Cancer du pénis
Chemotherapy
Chimiothérapie
Immunotherapy
Immunothérapie
Penile cancer
Targeted therapy
Thérapie ciblée
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
17
7
2020
Statut:
ppublish
Résumé
Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.
Identifiants
pubmed: 32620202
pii: S0007-4551(20)30274-5
doi: 10.1016/S0007-4551(20)30274-5
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
S17-S23Informations de copyright
Copyright © 2020 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.